Management of Hypertension Using Olmesartan Alone or in Combination by Xiaoshen Zhang et al.
REVIEW
Management of Hypertension Using Olmesartan
Alone or in Combination
Xiaoshen Zhang . Han Zhang . Yuxia Ma . Wenliang Che .
Michael R. Hamblin
Received: January 17, 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
ABSTRACT
Hypertension is one of the most significant and
consistent risk factors for many cardiovascular
diseases. The global prevalence of hypertension
has dramatically increased over recent years.
Life-style and genetic factors are generally con-
sidered to be primarily responsible for the
incidence of hypertension. Concerning the
high morbidity rate, setting up an updated
standard for hypertensive patients becomes
indispensable. According to the widely accepted
standard treatments for hypertension, these
four basic principles should be taken into
account: low dosage; medication should pro-
vide long term-control; combination therapies
are becoming common; personalized treat-
ments are a newer approach. In most patients
with hypertension, adequate control of BP can
be achieved with combined therapy. Therefore,
antihypertensive agents with complementary
mechanisms are now recommended. In this
review, we focus on the pharmacology, antihy-
pertensive efficacy, and adverse events (AEs) of
olmesartan medoxomil, either alone or in
combination with other antihypertensive med-
ications. In conclusion, olmesartan medoxomil,
is an angiotensin II receptor blocker with an
excellent efficacy in the reduction and stabi-
lization of blood pressure. When combined
with calcium channel blockers (CCBs) and
diuretics, olmesartan medoxomil has a better
effect on controlling BP and reducing AEs in
patients.
Keywords: Angiotensin II receptor blockers;
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Elevated blood pressure (BP) or hypertension
has become one of the biggest single contribu-
tors to the global burden of disease and global
mortality [1]. Hypertension causes the prema-
ture death of over 9.4 million people worldwide
every year according to a 23-year-long systemic
analysis [2], and was responsible for approxi-
mately 10.4 million deaths in 2013 [3]. At the
start of this century, it was estimated that nearly
972 million people worldwide had hyperten-
sion, and it was predicted that the prevalence
would increase to over 1.56 billion by 2025 [4].
The prevalence of hypertension among people
aged 35–64 years in the US population is about
30% [5] and about 44% in European countries
[6]. Moreover, hypertension continues to be
undertreated [7, 8].
The chief aim of the diagnosis and treatment
of hypertension is to reduce death and mor-
bidity from cardiovascular disease [9] (see
Fig. 1). With optimum control of BP, it is pos-
sible to prevent damage to many organ systems,
and the treatment of underlying vascular dis-
eases is also an important management objec-
tive [10]. Achieving BP goals is a persistent
challenge for hypertensive patients with low to
moderate risk, and reaching the figure of
130/80 mmHg is a goal for high-risk patients,
such as those with diabetes, cardiovascular dis-
ease, or renal disease [11]. The guidelines for the
management of hypertension in the United
States, Europe, and Japan recommend consid-
ering a combination of two drugs at the begin-
ning of treatment in high-risk patients or those
with grades 2–3 hypertension [12–14]. There-
fore, in clinical practice, two or more drugs with
different mechanisms of action are often cho-
sen, and are considered to have a better pro-
spect to achieve satisfactory BP control.
Olmesartan is classified as an angiotensin
receptor blocker (ARB).
METHODS
The literature searches were conducted in
March to April 2016 using PubMed and
Excerpta Medica Database (EMBASE) together
with the Web of Science database. We selected
influential randomized controlled trials in the
field of hypertension research. In brief, we used
keywords such as olmesartan medoxomil
monotherapy, or versus placebo or antihyper-
tensive mono or combination therapy (trial
duration at least 2 months). We included trials
with drugs in adults, men, and non-pregnant
women, with uncomplicated primary hyper-
tension. Trials that had oral antihypertensive
treatment with other angiotensin II receptor
blockers (ARBs), thiazide and thiazide-like
diuretics, calcium-channel blockers and
angiotensin-converting enzyme inhibitors
(ACEI), as comparators, were eligible for inclu-
sion. The contents of this article are based on
previously published studies and do not involve
any new studies of human or animal subjects
performed by any of the authors.
Discovery and Development
of Angiotensin Receptor Blockers
In 1898, the physiologist Robert Tigerstedt and
his student, Per Bergman, working at the
Karolinska Institute in Stockholm, Sweden,
injected rabbits with different kinds of kidney
extracts, and found some caused a rise in blood
pressure [15]. They named the active principle
‘‘renin’’, and suggested it was a protein due to its
water-soluble, non-dialyzable, and heat-labile
properties. However, this remarkable discovery
remained largely unexplored for almost 40
years. In the 1930s, Harry Goldblatt conducted
experiments in which he constricted the blood
flow to the kidneys in dogs, and found that
ischemia caused the kidneys to secrete a sub-
stance that caused vasoconstriction [16].
Although initially it was thought that this sub-
stance was the same as the renin discovered by
Tigerstedt, attempts to purify it produced less
hypertensive activity, rather than the higher
activity that was expected. In 1939, renin itself
was found not to cause the rise in blood pres-
sure, but rather was an enzyme that catalyzed
the formation of another substance that actu-
ally was responsible, initially named ‘‘an-
giotonin’’ and ‘‘hypertensin’’, and then the
compromise name ‘‘angiotensin’’ was agreed. It
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was found that renin acts on a serum a2-glob-
ulin produced by the liver called angiotensino-
gen, which has 453 amino acids. The cleavage
product is a small peptide called angiotensin I
(Ang I), which has ten amino acids, and is
cleaved by angiotensin-converting enzyme
(ACE) to form the eight-amino-acid angiotensin
II (Ang II, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe). The
most important receptor for Ang II is called
angiotensin II receptor type 1 or (AT1).
In the 1970s, it was found that Ang II raised
BP, and individuals with high levels of renin
activity in plasma were at increased risk of car-
diovascular disease [17]. The physiological
functions of angiotensin II in the cardiovascular
system have been fully explained and presented
in various review articles [18–21]. The major
actions of Ang II include potent vasoconstric-
tion effects of arterioles throughout the body;
decreased renal blood flow and increased tubu-
lar sodium reabsorption and water retention.
Ang II stimulates aldosterone and anti-diuretic
hormone (ADH) secretion via the hypothala-
mus pituitary-adrenal axis or the local system
(Fig. 2). With the introduction of ACE inhibi-
tors such as captopril in the late 1970s [22], it
was confirmed that pharmaceuticals that reduce
Ang II activity could treat hypertension.
The first attempts to develop useful Ang II
receptor (AT1) antagonists focused on
Fig. 1 Major compliances of hypertension
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angiotensin peptide analogs. Saralasin contains
amino acid replacements by sarcosine, valine,
and alanine (Sar-Arg-Val-Tyr-Val-His-Pro-Ala)
and is a partial agonist of the Ang II receptor
[23].
In the early 1980s it was found that some
imidazole-5-acetic acid derivatives diminished
blood pressure rise after administration of Ang II
in rats [24]. Two compounds, S-8307 and S-8308,
were later found to be promising non-peptide
Ang II receptor antagonists. Structural modifica-
tions were made, and the orally active, potent,
and selective nonpeptide AT1 receptor blocker
losartan was developed. In 1995 losartan was
approved for clinical use in the US, and since
then seven additional ‘‘sartans’’ have been
approved (irbesartan, olmesartan, candesartan,
valsartan, fimasartan, eprosartan, and azilsartan)
[25]. Three of these sartans (olmesartan, azilsar-
tan, and candesartan) are usually administered as
ester prodrugs. The goal of using an ester prodrug
is to improve on the ADME (absorption, distri-
bution, metabolism, excretion) properties of the
drug. In the case of olmesartan and azilsartan the
prodrug moiety is medoxomil (5-methyl-2-ox-
o-1,3-dioxol-4-yl)-methyl ester. olmesartan
Fig. 2 The mechanism of ACEI and ARB function in the RAS system
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medoxomil is hydrolyzed by several esterase
enzymes in the intestines releasing the active
drug, olmesartan, which is easily absorbed [26].
Choice of Medications for Hypertension
The first-choice of medication to be employed
for primary hypertension patients with addi-
tional complications such as heart failure,
coronary artery disease, and diabetes mellitus,
etc., are ACEI; this is accordance with guidelines
recommended by several medical societies.
However, since ACEI drugs inhibit ACE, which
also degrades bradykinin, bradykinin therefore
accumulates and can cause angioedema or
angioneurotic edema. This is a rapid swelling of
the dermis, subcutaneous tissue, mucosa, and
submucosal tissues (similar to an allergic reac-
tion) and can be life-threatening due to airway
blockage (Table 1).
Sartans or ARBs are known for their excellent
side-effect profiles, which have been shown to
be similar to those of placebos in several clinical
trials. Therefore, ARBs are used in some cases
when patients who are not tolerant to ACEIs.
ARBs can avert the incidence of this side effect,
and thus can also achieve better efficacy in
controlling BP. Previous studies suggested that
in addition to the antihypertensive effect, the
ARB might directly prevent organ damage [27].
Mostly, the combination therapy choice
with ARB for mild-to-severe hypertensive
patients range from CCB to diuretics, which are
two strongly effective and tolerable agents.
Since there is no report of severe drug conflict
among ARB, CCB, and diuretics, concomitant
use of these anti-hypertensive that act through
different pharmacological pathways is recom-
mended for patients with moderate-to-severe
hypertension and those who do not reach BP
goals with monotherapy [28].
Moreover, some clinical trials and
meta-analyses that have recently been pub-
lished have suggested that ARBs are not partic-
ularly effective in preventing cardiovascular
events, like severe cardiovascular diseases
(CVD), and may also have side effects such as
adverse renal effects [29–36]. This controversy
about the efficacy of ARBs in treating
hypertension and preventing cardiovascular
events emphasizes the necessity to select the
best agents for each particular patient for BP
control [37]. Some studies have brought into
question the use of ARBs for treating patients
with severe CVD or preventing patients from
developing CVD, because ARBs did not decrease
the morbidity and mortality of the study
patients [38–41]. For instance, one meta-analy-
sis explored the efficacy of ARBs in the preven-
tion of myocardial infarction and other
cardiovascular outcomes. The results showed,
when compared with placebo or active treat-
ment, that ARBs were ineffective in the pre-
vention of myocardial infarction (RR 0.99, 95%
CI 0.92–1.07), death, cardiovascular death, or
angina pectoris [38]. Moreover, another
meta-analysis investigated the efficacy of ACEI
and ARB in the prevention of CVD in patients
with diabetes and hypertension and revealed
that ACEI could significantly reduce the risk of
all-cause mortality by 13% (RR 0.87; 95% CI
0.78–0.98), incidence of cardiovascular deaths
by 17% (0.83; 0.70–0.99), and major cardiovas-
cular events by 14% (0.86; 0.77–0.95). However,
ARB did not show the same advantages [41].
Therefore, the choice of antihypertensive
drugs significantly depends on the individual
patients’ medical condition. For patients with
mild-to-moderate hypertension who are also
intolerant to ACEI, ARB is a good choice for BP
control. For patients with primary hypertension
who are tolerant to ACEI and have CVD such as
heart failure ACEI should be recommended due
to the fact that ACEI has a better ability to
protect renal function and prevent the inci-
dence of CVD.
The Pharmacology of Olmesartan
Pharmacodynamics Properties of Olmesartan
Medoxomil
Olmesartan medoxomil is a white to light yel-
lowish-white powder or crystalline powder with a
molecular weight of 558.6, and practically insol-
uble in water and sparingly soluble in methanol
[42]. It is an angiotensin II type 1 receptor antag-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































which plays a key role in the pathogenesis of
hypertension. Oral olmesartan, 10–40 mg once
daily, is recommended for the treatment of adult
patients with hypertension [43]. Besides, olme-
sartan blocks the action of angiotensin II by
bindingwithhigh selectivity to the angiotensin II
type 1 receptor and not to angiotensin II type 2
receptor [44]. It binds to the type 1 receptorwith a
highdegreeof insurmountabilityandwithgreater
affinity than most other ARBs. According to
studies in vivo, olmesartan dose-dependently
antagonized the vasoconstrictor and pressure
responses induced with angiotensin II [45].
Pharmacokinetics Properties of Olmesartan
Medoxomil
Olmesartan is rapidly and completely bio-ac-
tivated by ester hydrolysis to olmesartan dur-
ing absorption from the gastrointestinal tract.
Olmesartan is rapidly absorbed following oral
administration and is completely metabolized
to the pharmacologically active metabolite.
Steady-state levels are achieved within 3–-
5 days and no accumulation in plasma occurs
with once-daily dosing. The absolute bioavail-
ability of olmesartan is approximately 26%.
After oral administration, the peak plasma
concentration (Cmax) of olmesartan can be
reached after 1–2 h, and food does not affect
the bioavailability of olmesartan. In addition,
the volume of distribution is approximately
17 l. Olmesartan is highly bound to plasma
proteins (99%) and does not penetrate red
blood cells [46].
To our knowledge, olmesartan, as an orally
administered prodrug, is able to rapid and
complete converted into olmesartan during
absorption, and is virtually no further metabo-
lism of olmesartan [47]. Total plasma clearance
of olmesartan is 1.3 l/h, with a renal clearance
of 0.6 l/h. No components other than olmesar-
tan were detected in plasma following oral
administration of radiolabeled olmesartan in
healthy volunteers [48]. Besides, Cmax of olme-
sartan increases linearly with single oral doses
of olmesartan between 10 and 160 mg [49].
Approximately 35–50% of the absorbed dose is
recovered in urine while the remainder is
eliminated in feces via the bile [50].
The Clinical Use of Olmesartan Alone
or in Combination
Monotherapy of Olmesartan
The open-label, non-comparative, multi-centric
WINOVER study was reported concerning the
patient condition of olmesartan monotherapy
[51]. In this study, 8940 adults patients
([18 years) with essential hypertension as well
as co-morbidities such as angina, diabetes mel-
litus, or dyslipidemia were recruited. Patients
were treated with olmesartan tablet 20 or 40 mg
once daily for 6 months. After 3 and 6 months
from initiation of treatment with olmesartan,
the reduction of systolic blood pressure (SBP)
\140 mmHg and diastolic blood pressure (DBP)
\90 mmHg was observed as primary outcome.
As a result, baseline SBP/DBP of 164/100 mmHg
was reduced to 153/93, 145/89, 134/84, and
130/82 mmHg at the end of 15 days, 1, 3, and
6 months, respectively, both of which were
statistically significant (p\0.0001). Besides, the
consistent increase of percentage of responders
for both SBP and DBP from the 15th day to
6 months was observed. The mild-to-moderate
AEs rate was 0.08% in all patients, and with no
incidence of serious cases. As for the treatment
results at 6 months, 96.49% and 96.48% of
patients was rated as good when assessed by the
treating physicians, respectively, with no severe
clinical outcomes occurring. Another similar
study was the OLMEBEST study [52]. This
European, multinational, double-blind study
also revealed that olmesartan (20 mg tablet)
resulted in a mean reduction of 11.8 mmHg in
mean sitting diastolic blood pressure and
17.1 mmHg in mean sitting systolic blood
pressure from baseline. The adverse event rate
was 30.9%, and the majority of these events
were mild. It was also highlighted that olme-
sartan medoxomil 20 mg/day was well toler-
ated, with no severe clinical outcomes reported.
When compared with candesartan, olmesar-
tan performed more effectively in reducing
daytime and 24-h DBP and SBP revealed by
Brunner’s study [53]. This randomized, dou-
ble-blind, parallel-group study included 643
patients aged 19–86 years with mainly
mild-to-moderate essential hypertension,
which was conducted at 44 centers in Germany,
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Poland, and the Czech Republic. In the olme-
sartan group, the result showed that mean
decreases by 6.7, 8.4, and 9.3 mmHg from
baseline in daytime DBP, after the treating time
of week 1, 2, and 8, respectively. The result is
superior to the candesartan group (p\0.0126).
The mean 24-h DBP/SBP also showed significant
advantages in favor of olmesartan treatment.
No severe adverse clinical events occurred.
As for the comparison for other ARBs, Opar-
il’s [54] study showed that the reduction of sit-
ting cuff DBP with olmesartan (11.5 mmHg) was
significantly greater than with losartan, valsar-
tan, and irbesartan (8.2, 7.9, and 9.9 mmHg,
respectively). Drug-related AEs and discontinu-
ation were rare among all groups, with no sev-
ere adverse events reported. The authors
concluded that compared with other ARBs,
olmesartan is more effective in reducing cuff
DBP in patients with essential hypertension.
However, Smith DH’s study [55] suggested that
olmesartan was significantly more effective
than losartan or valsartan, its effects on mean
decrease from baseline in ambulatory blood
pressure (ABP) and its goal rates were numeri-
cally better.
There were also several studies comparing
olmesartan with amlodipine for mild-to-mod-
erate hypertension. Chrysant’s study [56]
revealed that though mean reductions in
ambulatory and seated BP were similar between
the two agents group and both were well toler-
ated at the recommended starting dose, more
patients in the olmesartan group achieved the
SBP goal of \130 mmHg and the DBP goal of
\85 mmHg. This conclusion was also con-
firmed by Chrysant’s further study [57].
Omboni performed a pooled analysis from
two recent identically designed trials [58]. The
two trials compared the head-to-head efficacy
and safety of olmesartan and ramipril in elderly
patients with essential hypertension with or
without metabolic syndrome. After 12 weeks of
treatment, BP reductions were greater (p\0.05)
with olmesartan (SBP 17.0 mmHg; 95% CI 18.4,
15.6; DBP 9.6 mmHg; 95% CI 10.4, 8.8) than
with ramipril (SBP 14.7 mmHg; 95% CI 16.1,
13.2; DBP 8.4 mmHg; 95% CI 9.2, 7.6) in
patients with metabolic syndrome. The BP
normalization rates of olmesartan were also
greater than ramipril (46.0 vs. 35.8%, p\0.01)
in these patients. The same result also occurred
in patients without metabolic syndrome and in
the subgroup of patients with valid ABP
recordings and metabolic syndrome. As for the
drug-related AEs, the proportion of patients was
comparable with (olmesartan 2.4 vs. ramipril
2.8%) and without (olmesartan 3.5 vs. ramipril
3.7%) metabolic syndrome. In conclusion,
olmesartan provides more effective BP control
than ramipril in elderly hypertensive patients
with and without metabolic syndrome was
made [59].
Also, some retrospective re-studies compared
the efficacy and safety of olmesartan
monotherapy with other ARBs, ACEIs, CCBs,
diuretics, and b-blockers monotherapy, in
which the results revealed that olmesartan
showed greater clinical superiority to the other
categories above [59, 60].
Olmesartan/Amlodipine Versus Amlodipine
or Olmesartan
A randomized, double-blinded clinical trial
investigated the efficacy and safety of olmesar-
tan (10 mg/20 mg/40 mg) and amlodipine
(5 mg/10 mg) alone and with all possible com-
binations of variable concentrations [61, 62].
The primary efficacy variable was the change
from baseline in mean sitting diastolic blood
pressure (SeDBP) and mean sitting systolic
blood pressure (SeSBP) at week 8. The propor-
tion of patients achieving BP targets at week 8
(\140/90 and\120/80 mm Hg) was also asses-
sed. The conspicuous features of this study are
that all of these efficacy assessments were
applied to pre-specified subgroups including
race (black and non-black), diabetes status, age
(\65 years, greater than or equal to 65 years)
and baseline body mass index (baseline 30 kg/
m2) and the data were analyzed between sub--
groups. According to the results, the reductions
of both SeDBP and SeSBP were significant for all
olmesartan monotherapy (p\0.05), amlodip-
ine monotherapy (p\0.0001) and amlodipine/
olmesartan combination therapy (p\0.0001)
regimens by week 8. Specially, the amlodipine/
olmesartan combination therapy with dosage of
10 and 40 mg/day achieved the greatest reduc-
tions in mean sitting blood pressure in all
Cardiol Ther
subgroups except SeSBP in non-Blacks group. As
for the safety profiles, the tolerability of sub-
groups with difficult-to-treat hypertension were
similar to their more easily treated counterparts
as well as the monotherapy-treated cohorts.
Only one serious adverse event (cerebrovascular
accident) was reported, occurring in a black,
obese female patient aged\65 years with type II
diabetes in the olmesartan medoxomil
20 mg/day group (Table 2).
A series of articles have reported that olme-
sartan/amlodipine combination produced ben-
efits in increasing insulin sensitivity and
decreasing inflammatory markers compared to
any of them, which can tremendously benefit
the hypertensive patients with multiple symp-
toms [63–67]. Sievers’s study found that com-
bined treatment with olmesartan and
amlodipine attenuated atherosclerotic lesion
progression, possibly due to anti-inflammatory




ARBs and CCBs are often co-administered for
treating hypertension. Former studies have
revealed that RAS inhibitors (ARB and ACEI)
and a CCB effectively decreased central SBP by
reducing arterial wave reflection [69]. Similarly,
the J-CORE study by Matsui [70] has fully
demonstrated that compared to the olmesartan
(20 mg)/HCTZ (12.5 mg), olmesartan (20 mg)/
azelnidipine (16 mg) combination resulted in
greater reductions in central SBP and arterial
stiffness, although there is no significant dif-
ference between the two combinations in 24-h
SBP.
To determine which combination performed
better, Daikuhara [71] conducted the OLCA
study, which was an open-label randomized
study aimed at untreated diabetic hypertensive
patients. At the beginning, 300 patients were
randomized to have either olmesartan
(20 mg/day) or candesartan (8 mg/day), with
150 participants in each group. There were no
differences between the two groups. The 115
patients in the olmesartan group and 121
patients in the candesartan group who did not
achieve the anti-hypertensive goal (130/
80 mmHg) within 12 weeks were assigned to
received add-on CCB therapy, treated with
azelnidipine 16 mg/day or amlodipine
5 mg/day for 24 weeks. There were similar pro-
portions of patients using insulin or oral
antidiabetic drugs in both groups, which did
not affect the result of this study. The result
showed that no significant difference between
the olmesartan and candesartan groups was
found in the first 12 weeks. As a result, the
olmesartan group achieved greater effect in
controlling blood pressure. In the following
24 weeks, mean deduction in clinic-measured
SBP/SDP of olmesartan and candesartan group
was 15.3 ± 4.8/7.1 ± 3.2 mmHg (both p\0.01)
and 14.5 ± 4.6/6.7 ± 3.1 mmHg (both p\0.01),
respectively. Also, the deduction of early
morning BP was 16.7 ± 5.0/8.8 ± 3.0 mmHg
(both p\0.01) and 13.0 ± 4.6/6.4 ± 3.1 mmHg
(both p\0.01). As for the clinical outcome, no
severe cases occurred, and none of these
patients withdrew due to adverse events. All of
these data indicate that both olmesartan and
candesartan had good antihypertensive effects,
with olmesartan possessing a more significant
antihypertensive effect. Furthermore, the
olmesartan group achieved significantly greater
home-measured early morning BP reduction
than the candesartan group (p\0.05).
Olmesartan/Amlodipine Versus Aliskiren/
Amlodipine
Axthelm et al. designed a study to investigate
the efficacy of aliskiren and amlodipine com-
bination therapy in hypertensive patients
whose BP is not adequately controlled by the
combination of olmesartan and amlodipine
[72]. This study had two 4-week phases, which
were noted as phase 1 and phase 2. Each of
these had the treatment protocol of olmesartan
40 mg/amlodipine 10 mg and aliskiren 300 mg/
amlodipine 10 mg, respectively. The author
switched patients from phase 1 to phase 2,
whose BPs were not adequately controlled.
Those whose BP was not controlled in phase 2
would be arranged for an optional 4-week
combination treatment of aliskiren 300 mg/
amlodipine 10 mg/HCTZ 12.5 mg. As a result,
342 patients who were included in phase 1 have












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































phase 2, 187 patients with uncontrolled hyper-
tension at the end of phase 1 obtained a further
SBP/DBP reduction of 5.1 mmHg/4.8 mmHg
(95% CI 3.7, 6.5)/(95% CI 3.8, 5.8) with the SBP/
DBP responder rates by 44.4%/51.3% and SBP
and DBP normalization by 36.4% (p\0.0001).
The 65 patients who received the optional
treatment obtained a further decrease of SBP/
DBP by 8.1/6.7 mmHg (p\0.0001). No deaths
or severe AEs were reported. In conclusion, the
aliskiren/amlodipine and aliskiren/amlodipine/
hydrochlorothiazide combination had achieved
a clinically and statistically greater reduction in
BP when the patient’s BP could not be normally




The SEVITENSION study compared the effects
of perindopril/amlodipine and olmesartan/am-
lodipine in decreasing central aortic blood
pressure [73]. Six hundred patients were enrol-
led in this study. At the beginning, the patients
received amlodipine 10 mg during a 2–4 weeks
run-in, and 486 of them were randomized to
receive 24 weeks of double-blind combination
treatment, with 244 patients having olmesar-
tan/amlodipine 40/10 mg and 242 patients
having perindopril/amlodipine 8/10 mg, with
optional hydrochlorothiazide added in patients
with inadequate BP control at weeks 4, 8, or 12.
The study design is presented in Fig. 3. The
absolute change in central systolic blood pres-
sure (CSBP) from baseline to the final value was
set as the primary efficacy variable. As for the
result, the CSBP reduction of olmesartan/am-
lodipine group was higher than perindopril/
amlodipine group, with the BP reduced by
14.5 ± 0.83 mmHg versus 10.4 ± 0.84 mmHg.
Also, olmesartan/amlodipine recipients
achieved significantly greater BP normalization
rates than the perindopril/amlodipine recipi-
ents (75.6 vs. 57.5%, p\0.0001). Notably, each
treatment was well tolerated, and the propor-
tion of patients with C1 drug-related treat-
ment-emergent adverse events (TEAEs) was
comparable to the olmesartan/amlodipine
(25.0%) and perindopril/amlodipine (25.7%)
groups, while the patients that discontinued
treatment due to a drug-related TEAE was 5.7%
in olmesartan/amlodipine group compared
with 7.5% in the perindopril/amlodipine group.
No severe clinical outcome was reported. In
conclusion, this study strongly suggested that
the combination of olmesartan/amlodipine was
superior to perindopril/amlodipine in reducing
CSBP as well as maintaining a higher rate of BP
normalization. The post hoc analysis of this
study further also supported the conclusion in
hypertensive patients with diabetes [74].
Olmesartan/Hydrochlorothiazide Versus
Olmesartan or Hydrochlorothiazide
In a randomized, double-blind, factorial design
study [50], Chrysant investigated the efficacy of
olmesartan (10, 20, or 40 mg/day)/hy-
drochlorothiazide (12.5 or 25 mg/day) with
accordingly six possible combination versus
each of the agents alone. In total, 502 patients
in 12 groups including placebo received their
treatment regimens throughout the 8-week
experiment. The change in mean trough SeDBP
from baseline at week 8 was set as the primary
endpoint. The author did not compare BP
reductions with different combination doses,
which was probably a limitation. The result still
suggested that olmesartan/HCTZ led to greater
reductions in both SeDBP and SeSBP at week 8
than each of the agents and dosage alone. The
reductions of SeSBP/SeDBP in the combined
group of olmesartan/HCTZ 20/12.5 mg, olme-
sartan/HCTZ 40/25 mg, and placebo were 3.3/
8.2 mmHg (95% CI 6.0, 10.3)/(95% CI 6.0,
10.3), 20.1/16.4 mmHg (95% CI 17.1, 23.0)/
(95% CI 14.7, 18.1), and 26.8/21.9 mmHg (95%
CI 22.8, 30.8)/(95% CI 19.5, 24.3), respectively.
The result indicated that olmesartan/HCTZ
40/25 mg combination achieved the greatest
reduction, and the highest responder rate
(92.3%) and control rates (79.5% for diastolic
and 87.2% for systolic) were also observed in
the olmesartan/HCTZ 40/25 mg/day group. As
for drug safety, investigators noted that all
dosages of monotherapy and combination
therapy were safe and well tolerated, and no
significant incidence of treatment-emergent
adverse effects was reported. The overall dis-
continuation rate was 2.0% and was not the
result of an AE or related to dosage of any study
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medication. No severe clinical outcomes were
reported.
Olmesartan/Amlodipine/Hydrochlorothiazide
It is recommended that patients with uncon-
trolled hypertension treated with two antihy-
pertensive agents may require a combination of
three agents to achieve satisfied BP. Oparil
conducted the TRINITY study [75] to determine
whether the triple combination of olmesartan,
amlodipine, and HCTZ had better efficacy and
safety conditions compared with dual combi-
nations in patients aged C18 years who had
moderate-to-severe hypertension, who have the
SeSBP C140/100 or C160/90 mmHg. The study
design and detail is presented in Fig. 4. After a
3-week washout period with no study medica-
tion and a 12-week double-blind treatment
(olmesartan 40 mg/amlodipine 10 mg/HCTZ
25 mg, olmesartan 40 mg/amlodipine 10 mg,
olmesartan 40 mg/HCTZ 25 mg, and amlodip-
ine 10 mg/HCTZ 25 mg), the study found that
triple combination treatment was associated
with significantly greater mean reductions in
seated BP compared with the dual combina-
tions. The reduction of SeDBP and SeSBP in
triple combination group is 21.8 and
37.1 mmHg, respectively. While in the dual
combination group, the SeDBP and SeSBP
reductions ranged from 15.1–18.0 mmHg to
27.5–30.0 mmHg (p\0.001), respectively. As
for BP achieving rate, patients in triple combi-
nation treatment reached BP targets with sig-
nificantly higher proportion compared to the
dual combinations at week 12 (olmesartan/am-
lodipine/HCTZ: 69.9%, olmesartan/amlodipine:
52.9%, olmesartan/HCTZ: 53.4%, and
amlodipine/HCTZ: 41.1%, respectively
[p\0.001]). All of the treatments in this study
were generally well tolerated, with 1.5% of
patients experiencing serious AEs.
In the TRINITY ABP sub-study, the authors
used the ABP monitoring (ABPM) method to
compare the clinical benefits between the same
triple combination and the same dual combi-
nation, in which they found that the triple
combination demonstrated superior efficacy
and sustained reductions in ABP compared
with its dual-combination components. ABPM
is currently recommended by the American
Society of Hypertension as the best method for
assessing cardiovascular risk in individuals
with hypertension [76]. Therefore, the result
supports the idea that triple combination
therapy is better than the each of the dual
combinations.
Another TRINITY sub-study revealed the fact
that triple combination treatment could also
Fig. 3 The study design and treatment procedure of the SEVITENSION study [73]
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benefit patients with different pathological
conditions, such as diabetes, chronic kidney
disease, and chronic cardiovascular disease [56].
Factors like age, ethnicity, and race did not
affect the treatment results in the triple com-
bination group compared with the dual com-
bination treatment group [77–80].
Safety and tolerability
Safety and tolerability for oral olmesartan in
patients with moderate-to-severe hypertension
were continually investigated [81, 82]. An inte-
grated analysis of efficacy and safety of olme-
sartan demonstrated that the AEs profile
observed with olmesartan monotherapy and
combination therapy was approximate to pla-
cebo, and dizziness was the only event that
occurred more in patients with olmesartan
comparing with placebo [11]. Also, olmesartan
was with less AEs compared with valsartan,
losartan, and amlodipine during the treatment
period. Besides, AEs associated with the combi-
nation of olmesartan and HCTZ were generally
mild-to-moderate in severity [83]. The safety of
olmesartan/HCTZ was well evaluated in 1243
hypertensive patients. As a result, treatment
with olmesartan/HCTZ was well tolerated.
Dizziness, flushed face, and upper respiratory
tract infections were more often reported in
olmesartan/HCTZ recipients than placebo
recipients [84]. However, adverse events were
generally mild, transient, and had no relation-
ship with the dose of olmesartan/HCTZ. There
was also no difference of AEs between olmesar-
tan/HCTZ and placebo among gender, age, and
race groups.
The best-known severe adverse event associ-
ated with olmesartan is sprue-like enteropathy,
according to several case reports and research
articles [85–90]. Rubio-Tapia et al. firstly repor-
ted that 22 olmesartan recipients who suffered
from chronic diarrhea could recover from the
syndrome after stopping olmesartan therapy
[91]. Generally, the symptoms of olmesar-
tan-induced enteropathy are watery diarrhea,
abdominal pain, weight loss, and nausea, and
symptoms can be ameliorated after stopping the
medication. Pathology studies showed clear
inflammatory changes in the intestinal mucosa,
Fig. 4 Study design of the TRINITY study. OM olmesartan medoxomil, AML amlodipine besylate, HCTZ
hydrochlorothiazide [75]
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such as villous blunting with near-complete
villous atrophy of the small intestinal mucosa
[88, 92–94]. Although the pathogenic mecha-
nism of this disease remains unclear, some
hypotheses were presented. Laniro et al. and
Rubio-Tapia proposed that a cell-mediated
delayed hypersensitivity reaction could be the
plausible explanation for these changes [95, 96].
Another hypothesis suggested that the mecha-
nism of action could involve inhibition of the
transforming growth factor beta (TGF-b) path-
way leading to a breakdown of the intestinal
immune homeostasis, thus causing a patholog-
ical variation [97]. Therefore, early identifica-
tion of olmesartan-induced enteropathy
patients is important, and prompt discontinu-
ation of the medication is strongly recom-
mended [98].
In addition, combined therapy using olme-
sartan has been reported to have a positive
effect on heart rate variability, which is an
independent risk factor in predicting the sever-
ity and prognosis of cardiovascular disease. It
was also reported that the use of olmesartan had
an obvious BP stabilization for elderly recipi-
ents, especially in controlling the morning BP
surge [99]. In addition, patients with chronic
renal diseases are not suggested to be suit-
able for combined therapy owing to increased
AEs [100].
CONCLUSIONS
Olmesartan medoxomil, as an angiotensin II
receptor antagonist, shows good efficacy in BP
reduction and stabilization. When combined
with HCTZ or amlodipine, olmesartan has a
better effect on controlling BP and reducing the
AE rate. In conclusion, olmesartan alone or in
combination with other anti-hypertensive
agents is effective and well tolerated for the
management of hypertension in patients.
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